Last reviewed · How we verify
Bacteriotherapy
At a glance
| Generic name | Bacteriotherapy |
|---|---|
| Sponsor | Tel-Aviv Sourasky Medical Center |
| Modality | Biologic |
| Therapeutic area | Infectious Disease |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Rectal Bacteriotherapy, Fecal Microbiota Transplantation or Oral Vancomycin Treatment of Recurrent Clostridium Difficile Infections (Phase 3)
- A Randomized Controlled Multicenter Trial of a Five Day Course of Oral Colistin and Neomycin Followed by Restoration of the Gut Microbiota Using Fecal Transplantation to Eradicate Intestinal Carriage (Phase 2)
- Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection (Phase 2)
- A Randomized Controlled Study of Efficacy, Safety and Durability of Fecal Microbiota Transplantation in Adult Patients With Slow Transit Constipation (Phase 2)
- Freeze-dried, Capsulized Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection (Phase 1)
- HPVinHIV: Study of Anal HPV Infection in the Setting of HIV Infected Individuals (NA)
- A Randomized Controlled Trial of Fecal Biotherapy for the Induction of Remission in Active Ulcerative Colitis (Phase 2)
- COmparative Effectiveness of IntestinaL MicrobiOta Versus VaNcomycin for Primary C. Difficile Infection - RandomiZEd Trials (Phase 3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bacteriotherapy CI brief — competitive landscape report
- Bacteriotherapy updates RSS · CI watch RSS
- Tel-Aviv Sourasky Medical Center portfolio CI